Medpace (NASDAQ:MEDP) Now Covered by Analysts at BMO Capital Markets

Research analysts at BMO Capital Markets began coverage on shares of Medpace (NASDAQ:MEDP) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “market perform” rating and a $600.00 price target on the stock. BMO Capital Markets’ price target would indicate a potential downside of 0.39% from the company’s previous close.

Other equities analysts have also issued reports about the company. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and upped their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. William Blair reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $487.18.

Medpace Price Performance

Shares of MEDP stock traded up $4.72 during trading hours on Thursday, reaching $602.32. The company had a trading volume of 63,499 shares, compared to its average volume of 417,344. The company has a market cap of $16.97 billion, a price-to-earnings ratio of 41.99, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. Medpace has a 12 month low of $250.05 and a 12 month high of $625.00. The business has a fifty day simple moving average of $535.14 and a 200-day simple moving average of $419.62.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts expect that Medpace will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, President Jesse J. Geiger sold 21,503 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president owned 15,000 shares in the company, valued at $8,934,900. This trade represents a 58.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 134,211 shares of company stock valued at $74,459,958 over the last three months. Corporate insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Mawer Investment Management Ltd. purchased a new position in shares of Medpace during the first quarter valued at approximately $212,131,000. Vulcan Value Partners LLC grew its holdings in shares of Medpace by 221.6% in the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after acquiring an additional 224,578 shares during the period. Norges Bank bought a new position in Medpace in the second quarter valued at about $66,597,000. Clarkston Capital Partners LLC purchased a new position in Medpace in the second quarter worth about $40,569,000. Finally, Bares Capital Management Inc. increased its position in shares of Medpace by 319.2% during the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after purchasing an additional 119,608 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.